Dr. Amelia Villagomez, an expert in broad-spectrum micronutrient therapy, discusses using micronutrients alongside existing interventions for mental health conditions like ADHD and mood instability. The podcast explores clinical cases showcasing improvements in mood, focus, and emotional regulation through personalized treatment approaches.

In this episode, we discuss the groundbreaking FDA approval of zuranolone, the first oral medication specifically targeting postpartum depression. Could zuranolone's novel mechanism of action as an allopregnanolone agonist herald a new era of rapid-onset, targeted treatments for this debilitating condition affecting 1 in 8 new mothers? Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 54 Zuranolone for the Treatment of Postpartum Depression

Dr. Amelia Villagomez discusses using micronutrient supplements to treat mental health conditions such as anxiety and ADHD. She shares tips on dosing, managing side effects, and incorporating nutrients into recipes for easier consumption.

In this episode, we examine whether first-trimester exposure to the antipsychotic olanzapine increases the risk of major fetal malformations. Does stopping medication abruptly also carry risks? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 14 Risk of Major Malformations Following First-Trimester Exposure to Olanzapine

Amelia Villagomez, M.D., a medical doctor specializing in micronutrient safety, discusses critical insights on broad-spectrum micronutrient formulas and their implications for mental health treatment. She explores potential interactions with medications, including psychotropic and CNS drugs. The conversation delves into how these supplements can affect surgical procedures involving anesthesia and emphasizes the importance of careful monitoring and further research to ensure patient safety.

In this episode, we explore the potential of NSAIDs in delirium prevention. However, NSAIDs come with risks, such as GI bleeding or kidney injury. Can NSAIDs really help prevent delirium, and if so, how? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 54 Use of NSAIDs for Delirium Risk Reduction

Exploring the use of micronutrient formulas in mental health care, focusing on safety and efficacy. Examining potential side effects and benefits of broad-spectrum micro-nutrients in treating conditions like ADHD, anxiety, and depression. Discussing the role of nutritional psychiatry and the need for further research.

In this episode, we discuss an insightful study by Strawn et al. that utilized a mega-analysis approach, combining data on over 900 MDD patients across lifespan treatment trials to elucidate differences in antidepressant treatment outcomes based on patient age. Does antidepressant efficacy differ across developmental stages—children, adolescents, and adults? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 13 Age's Impact on Antidepressant Response

What are some common signs that suggest a cancer patient may be developing delirium? In this episode, we explore the complex issue of delirium in advanced cancer patients. We discuss important considerations regarding medication management, the importance of distinguishing terminal from reversible delirium, and the role of antipsychotics and benzodiazepines in treatment. Faculty: Jaroslava Salman, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Depression, Anxiety, and Delirium in Patients With Cancer Management of Delirium in Patients With Cancer

In this episode, we discuss the treatment of agranulocytosis or neutropenia in patients on clozapine therapy, a rare yet serious scenario that clinicians may encounter. We delve into the possibility of rechallenging clozapine treatment after such an event and explore the use of colony-stimulating factors. What's the likelihood of agranulocytosis while prescribing clozapine long term? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 53 The Impact of Colony-Stimulating Factor on Clozapine Rechallenge Outcomes